Treatment of Childhood Complicated Community-Acquired Pneumonia with Amoxicillin/Sulbactam

References

• Mathers CD, Murray CJL, Lopez AD, Stein C. The global burden of disease 2000 project: objectives, methods, data sources and preliminary results. Evidence and information for policy. (EIP). Geneva: World Health Organization, 2001.
   Google Scholar
• Health in the Americas. Pan American Health Organization. 2002; Vol 2; 440–53.
   Google Scholar
• Melgarejo C, Lovera D, Arbo A. Etiologia actual de las neumonias complicadas con derrame pleural en un centro de referencia. Pediatria (Paraguay) 2003; 30: S26.
   Google Scholar
• Moreira V, Lovera D, Arbo A. Empyema Pleural in chil-dren. Clin Infect Dis 1996; 23: 924.
   Google Scholar
• Allende I, Arbo A. Patrôn de susceptibilidad a antibieyti-cos de cepas invasivas de Haemophilus influenzae tipo b en Paraguay. Pediatria (Paraguay) 1998; 25: 15–17.
   Google Scholar
• W.H.O. Program for the Control of Acute Respiratory Infections. Acute respiratory infections in children: case man-agement in small hospitals in developing countries. A manual for doctors and other senior health workers. W.H.O./ARI/90.5. World Health Organization, Geneva, Switzerland. 1990.
   Google Scholar
• Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998: 42: 2375–9.
   PubMed Web of Science ®Google Scholar
• Bantar C, Bavestrello L, Curcio D, Jasovich A and the Consensur Group. Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur). J Chemother 2002; 14, suppl. n. 4, 1-24.
   Google Scholar
• Aronoff SC, Jacobs MR, Johenning S, Yamabe S. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amox-icillin or ampicillin. Antimicrob Agents Chemother 1984; 26: 580–2.
   PubMed Web of Science ®Google Scholar
• Mansilla E. An update of acute otitis media manage-ment: Experience with the amoxicillin-sulbactam combination. Drugs Today (Barc) 2001; 37: 189–91.
   PubMed Web of Science ®Google Scholar
• Nelson JD Oral antibiotic therapy for serious infections in hospitalized patients. J Pediatr 1978; 92: 175–6
   Google Scholar
• Isenberg HD. Clinical microbiology procedures hand-book. Washington, DC: American Society of Microbiology, 1994.
   Google Scholar
• Deanna LK. In vitro testing of antimicrobial agents. Semin Pediatr Infect Dis 1998; 9: 281–91.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards, 2002; document no. NCCLS M100–S12.
   Google Scholar
• Fass RJ, Barnishan J. Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae indepen-dent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analy-ses. J Antimicrob Chemother 2001: 48: 609–15.
   PubMed Web of Science ®Google Scholar
• Young MJ, Bresnitz EA, Strom BL. Sample size nomo-grams for interpreting negative clinical studies. Ann Intern Med 1983; 99: 248–51.
   PubMed Web of Science ®Google Scholar
• Jasovich A, Soutric J, Morera G et al. Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model. J Chemother 2002; 14: 591–6.
   Google Scholar
• Bradley JS. Management of community-acquired pedi-atric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. Pediat Infect Dis J 2002; 21: 592–8.
   PubMed Web of Science ®Google Scholar
• McIntosh K: Community-acquired pneumonia in chil-dren. N Engl J Med 2002; 346: 429–37.
   Google Scholar
• Kaplan SL, Mason EO Jr. Management of infections due to antibiotic resistant Streptococcus pneumoniae. Clin Microbiol Rev 1998; 11: 628–44.
   PubMed Web of Science ®Google Scholar
• Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. A Report from the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch Intern Med 2000; 160: 1399–07.
   Google Scholar
• Kaplan SL, Mason Jr EO, Barson JR. WJ et al. Outcome of invasive infections outside the central nervous sys-tem caused by Streptococcus pneumoniae isolates nonsus-ceptible to ceftriaxone in children treated with beta-lactam antibiotics. Pediatr Infect Dis J 2001; 20: 392-6.
   PubMed Web of Science ®Google Scholar
• Dowell SF, Smith T, Leversedge K, Snitzer J. Failure of treatment of pneumonia associated with highly resistant pneu-mococci in a child. Clin Infect Dis 1999; 29: 462–3.
   PubMed Web of Science ®Google Scholar
• Esposito S, Bosis S, Cavagna R et al. Characteristics of Streptococcus pneumoniae and atypical bacterial infec-tions in children two to five years of age with community-acquired pneumonia. Clin Infect Dis 2002; 35: 1345–52.
   Google Scholar
• Daschner FD, Gier E, Lentzen H, Kaiser D, Bamberg P. Penetration into the pleural fluid after bacampicillin and amoxycillin. J Antimicrob Chemother 1981; 7: 585–8.
   PubMed Web of Science ®Google Scholar
• Lechi A, Arosio E, Xerri L, Mengoli C, Montesi G, Ghidini O. The kinetics of cefuroxime in ascitic and pleural fluid. Int J Clin Pharmacol Ther Toxicol 1982; 20: 493–6.
   PubMed Web of Science ®Google Scholar
• Mason EO, Lamberth LB, Kershaw NL, et al. Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis. J Antimicrob Chemother 2000; 45: 623–31.
   PubMed Web of Science ®Google Scholar